Clinical Trial Update: Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of a live-attenuated HPIV3 vectored vaccine expressing Ebola Zaire glycoprotein has been terminated; the Ebola Virus Disease study will…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• HPIV3-vectored Ebola vaccine (EBOV GP)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Ebola Virus Disease | Phase 1 | Status: TERMINATED